DrugPatentWatch Database Preview
Pfizer Company Profile
What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?
PFIZER has one hundred and fifty-five approved drugs.
There are fifty-one US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand four hundred and twenty-five patent family members on PFIZER drugs in eighty countries and one hundred and forty-six supplementary protection certificates in fourteen countries.
Summary for Pfizer
| International Patents: | 1425 |
| US Patents: | 51 |
| Tradenames: | 122 |
| Ingredients: | 108 |
| NDAs: | 155 |
| Drug Master File Entries: | 3 |
| Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
| PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | TROVAN PRESERVATIVE FREE | alatrofloxacin mesylate | INJECTABLE;INJECTION | 020760-002 | Dec 18, 1997 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Pfizer | DIFLUCAN | fluconazole | TABLET;ORAL | 019949-001 | Jan 29, 1990 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Pfizer | PFIZERPEN-A | ampicillin/ampicillin trihydrate | FOR SUSPENSION;ORAL | 062049-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Pfizer | URESE | benzthiazide | TABLET;ORAL | 012128-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Pfizer | DIFLUCAN | fluconazole | TABLET;ORAL | 019949-004 | Jun 30, 1994 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-001 | Oct 16, 2018 | RX | Yes | No | 8,420,650 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Pfizer | GLUCOTROL | glipizide | TABLET;ORAL | 017783-002 | May 8, 1984 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer Inc | FRAGMIN | dalteparin sodium | INJECTABLE;SUBCUTANEOUS | 020287-004 | Jan 30, 1998 | 4,303,651 | ➤ Sign Up |
| Pfizer | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-006 | Jan 30, 2004 | 5,969,156*PED | ➤ Sign Up |
| Pfizer | DIFLUCAN | fluconazole | TABLET;ORAL | 019949-002 | Jan 29, 1990 | 4,404,216*PED | ➤ Sign Up |
| Pfizer | VANSIL | oxamniquine | CAPSULE;ORAL | 018069-001 | Approved Prior to Jan 1, 1982 | 3,903,283 | ➤ Sign Up |
| Pfizer | ZITHROMAX | azithromycin | TABLET;ORAL | 050730-001 | Jun 12, 1996 | 6,268,489 | ➤ Sign Up |
| Pfizer | GEODON | ziprasidone mesylate | INJECTABLE;INTRAMUSCULAR | 020919-001 | Jun 21, 2002 | 6,110,918 | ➤ Sign Up |
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | 4,681,893*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Tablets | 5 mg/80 mg | ➤ Subscribe | 2009-04-07 |
| ➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
| ➤ Subscribe | Tablets | 25 mg and 50 mg | ➤ Subscribe | 2004-11-19 |
| ➤ Subscribe | Tablets | 20 mg and 40 mg | ➤ Subscribe | 2010-03-29 |
| ➤ Subscribe | Capsules | 200 mg/30 mg | ➤ Subscribe | 2004-12-27 |
| ➤ Subscribe | Sublingual Tablets | 0.6 mg | ➤ Subscribe | 2011-12-29 |
| ➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
| ➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
| ➤ Subscribe | Tablets | 150 mg and 200 mg | ➤ Subscribe | 2005-11-09 |
| ➤ Subscribe | Tablets | 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg | ➤ Subscribe | 2006-12-29 |
| ➤ Subscribe | Tablets | 2.5 mg/40 mg | ➤ Subscribe | 2009-09-17 |
| ➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2004-10-25 |
| ➤ Subscribe | Sublingual Tablets | 0.3 mg, 0.4 mg and 0.6 mg | ➤ Subscribe | 2005-10-19 |
| ➤ Subscribe | Capsules | 200 mg/38 mg | ➤ Subscribe | 2016-02-16 |
| ➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
Premature patent expirations for PFIZER
International Patents for Pfizer Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2004026283 | ➤ Sign Up |
| European Patent Office | 1230209 | ➤ Sign Up |
| Czech Republic | 303875 | ➤ Sign Up |
| Ukraine | 85706 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 03062236 | ➤ Sign Up |
| Cyprus | 1108850 | ➤ Sign Up |
| Hungary | 0900587 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2017 00013 | Denmark | ➤ Sign Up | PRODUCT NAME: KOMBINATION AF INSULIN DEGLUDEC OG LIRAGLUTID; NAT. REG. NO/DATE: EU/1/14/947 20140922; FIRST REG. NO/DATE: CH 65041 20140912 |
| C/GB04/036 | United Kingdom | ➤ Sign Up | PRODUCT NAME: INSULIN DETEMIR, NEB29- TETRADECANOYL- DES(B30) HUMAN INSULIN; NATL REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: CH 56370, 56311, 56372 20031110 |
| C/GB08/005 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
| C/GB11/010 | United Kingdom | ➤ Sign Up | PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK |
| 01C/013 | Belgium | ➤ Sign Up | PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115 |
| 00445 | Netherlands | ➤ Sign Up | PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016 |
| C/GB02/037 | United Kingdom | ➤ Sign Up | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
